{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:21:13Z","timestamp":1769520073869,"version":"3.49.0"},"reference-count":79,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The world is now apparently at the last\/recovery stage of the COVID-19 pandemic, starting from 29 December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the progression of time, several mutations have taken place in the original SARS-CoV-2 Wuhan strain, which have generated variants of concern (VOC). Therefore, combatting COVID-19 has required the development of COVID-19 vaccines using several platforms. The immunity induced by those vaccines is vital to study in order to assure total protection against SARS-CoV-2 and its emerging variants. Indeed, understanding and identifying COVID-19 protection mechanisms or the host immune responses are of significance in terms of designing both new and repurposed drugs as well as the development of novel vaccines with few to no side effects. Detecting the immune mechanisms for host protection against SARS-CoV-2 and its variants is crucial for the development of novel COVID-19 vaccines as well as to monitor the effectiveness of the currently used vaccines worldwide. Immune memory in terms of the production of neutralizing antibodies (NAbs) during reinfection is also very crucial to formulate the vaccine administration schedule\/vaccine doses. The response of antigen-specific antibodies and NAbs as well as T cell responses, along with the protective cytokine production and the innate immunity generated upon COVID-19 vaccination, are discussed in the current review in comparison to the features of naturally induced protective immunity.<\/jats:p>","DOI":"10.3390\/v14112541","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T03:57:44Z","timestamp":1668743864000},"page":"2541","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4837-221X","authenticated-orcid":false,"given":"Rashed","family":"Noor","sequence":"first","affiliation":[{"name":"Department of Life Sciences (DLS), School of Environment and Life Sciences (SELS), Independent University, Bangladesh (IUB), Dhaka 1229, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"ref_1","unstructured":"WHO (World Health Organization) (2022, November 10). Coronavirus Diseases (COVID-19) Dashboard. Updated on 5:41 pm CET, Available online: https:\/\/covid19.who.int\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"eabn4947","DOI":"10.1126\/science.abn4947","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa","volume":"376","author":"Pulliam","year":"2022","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e61390","DOI":"10.7554\/eLife.61390","article-title":"ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities","volume":"9","author":"Grandvaux","year":"2020","journal-title":"eLife"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Sinai Immunology Review Project Immunology of COVID-19: Current State of the Science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Aliyari, S.R., Quanquin, N., Pernet, O., Zhang, S., Wang, L., and Cheng, G. (2022). The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2. Pathogens, 11.","DOI":"10.3390\/pathogens11050538"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Belleudi, V., Rosa, A.C., Poggi, F.R., Armuzzi, A., Nicastri, E., Goletti, D., Diamanti, A.P., Davoli, M., Agabiti, N., and Addis, A. (2021). Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112388"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00203-021-02265-y","article-title":"A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV)","volume":"203","author":"Noor","year":"2021","journal-title":"Arch. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13578-021-00643-z","article-title":"SARS-CoV-2: From its discovery to genome structure, transcription, and replication","volume":"11","author":"Brant","year":"2021","journal-title":"Cell Biosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s42003-021-01754-6","article-title":"Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants","volume":"4","author":"Wang","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"167265","DOI":"10.1016\/j.jmb.2021.167265","article-title":"Mechanisms of Antiviral Immune Evasion of SARS-CoV-2","volume":"434","author":"Beyer","year":"2022","journal-title":"J. Mol. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaci.2020.10.040","article-title":"Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19","volume":"147","author":"Cervia","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/14760584.2022.2042257","article-title":"Clinical development and approval of COVID-19 vaccines","volume":"21","author":"Kalinke","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/s41467-021-21444-5","article-title":"Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19","volume":"12","author":"Wheatley","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijid.2022.04.027","article-title":"Humoral and cellular responses to spike of \u03b4 SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases","volume":"121","author":"Petrone","year":"2022","journal-title":"Int. J. Infect. Dis. Off. Publ. Int. Soc. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rubio-Casillas, A., Redwan, E.M., and Uversky, V.N. (2022). SARS-CoV-2: A Master of Immune Evasion. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061339"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/17476348.2022.2057299","article-title":"SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond","volume":"16","author":"Ong","year":"2022","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Andrews","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"856657","DOI":"10.3389\/fimmu.2022.856657","article-title":"Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components","volume":"13","author":"Sorrentino","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2037384","DOI":"10.1080\/21645515.2022.2037384","article-title":"Longevity of immunity following COVID-19 vaccination: A comprehensive review of the currently approved vaccines","volume":"18","author":"Jamshidi","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sa Ribero, M., Jouvenet, N., Dreux, M., and Nisole, S. (2020). Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008737"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Huang, W.T., Weng, S.W., Tzeng, H.T., Yen, F.C., Chiang, Y.S., and You, H.L. (2022). Lymphocyte Subpopulations Associated with Neutralizing Antibody Levels of SARS-CoV-2 for COVID-19 Vaccination. Vaccines, 10.","DOI":"10.3390\/vaccines10091550"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1590\/s1677-5538.ibju.2020.0872","article-title":"SARS-CoV-2 and Multi-Organ damage\u2014What men\u2019s health specialists should know about the COVID-19 pathophysiology","volume":"47","author":"Teixeira","year":"2021","journal-title":"Int. Braz. J. Urol. Off. J. Braz. Soc. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: A randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/22221751.2021.2014284","article-title":"A second functional furin site in the SARS-CoV-2 spike protein","volume":"11","author":"Zhang","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"316","DOI":"10.7150\/thno.49713","article-title":"Immunopathogenesis and treatment of cytokine storm in COVID-19","volume":"11","author":"Kim","year":"2021","journal-title":"Theranostics"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tang, X.D., Ji, T.T., Dong, J.R., Feng, H., Chen, F.Q., Chen, X., Zhao, H.Y., Chen, D.K., and Ma, W.T. (2021). Pathogenesis and Treatment of Cytokine Storm Induced by Infectious Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222313009"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s00284-022-02877-7","article-title":"Association of Gut Microbiota with Inflammatory Bowel Disease and COVID-19 Severity: A Possible Outcome of the Altered Immune Response","volume":"79","author":"Kaushal","year":"2022","journal-title":"Curr. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1016\/j.csbj.2021.07.023","article-title":"Immune evasion of SARS-CoV-2 from interferon antiviral system","volume":"19","author":"Min","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.chom.2021.05.004","article-title":"Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19","volume":"29","author":"Lowery","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12985-022-01783-5","article-title":"The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity","volume":"19","author":"Gu","year":"2022","journal-title":"Virol. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-022-00967-3","article-title":"STING, a critical contributor to SARS-CoV-2 immunopathology","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Znaidia, M., Demeret, C., van der Werf, S., and Komarova, A.V. (2022). Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options. Viruses, 14.","DOI":"10.3390\/v14061247"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"108916","DOI":"10.1016\/j.celrep.2021.108916","article-title":"Sarbecovirus ORF6 proteins hamper induction of interferon signaling","volume":"34","author":"Kimura","year":"2021","journal-title":"Cell Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","article-title":"Humoral Immune Response to SARS-CoV-2 in Iceland","volume":"383","author":"Gudbjartsson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1038\/s41467-020-17292-4","article-title":"Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia","volume":"11","author":"Meschiari","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6657894","DOI":"10.1155\/2021\/6657894","article-title":"Analysis of Lymphocyte Subpopulations and Cytokines in COVID-19-Associated Pneumonia and Community-Acquired Pneumonia","volume":"2021","author":"Liu","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100355","DOI":"10.1016\/j.xcrm.2021.100355","article-title":"Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"eabe0240","DOI":"10.1126\/sciimmunol.abe0240","article-title":"Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome","volume":"5","author":"Powell","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41591-020-0819-2","article-title":"Breadth of concomitant immune responses prior to patient recovery: A case report of non-severe COVID-19","volume":"26","author":"Thevarajan","year":"2020","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s11033-021-07020-6","article-title":"Neutralizing antibody: A savior in the Covid-19 disease","volume":"49","author":"Gupta","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"eabd2223","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Stankov","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s40588-021-00174-8","article-title":"COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks","volume":"8","author":"Noor","year":"2021","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: From basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e002036","DOI":"10.1136\/rmdopen-2021-002036","article-title":"Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: A systematic review and meta-analysis of 1342 patients","volume":"8","author":"Schietzel","year":"2022","journal-title":"RMD Open"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.7150\/ijbs.73583","article-title":"Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: A systemic review","volume":"18","author":"Chen","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s42269-022-00787-z","article-title":"COVID-19 vaccines: Their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants","volume":"46","author":"Noor","year":"2022","journal-title":"Bull. Natl. Res. Cent."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"740249","DOI":"10.3389\/fimmu.2021.740249","article-title":"ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients","volume":"12","author":"Aiello","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1093\/cid\/ciab845","article-title":"Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged \u22656 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial","volume":"75","author":"Zhu","year":"2022","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"ref_64","unstructured":"Janssen Biotech (2022, October 08). COVID-19 Vaccine Ad26.COV2.S. Sponsor Briefing Document (Vaccines and Related Biological Products Advisory Committee, 2021), Available online: https:\/\/www.fda.gov\/media\/146217\/download."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coviro.2021.04.008","article-title":"SARS-CoV-2 vaccines\u2014The biggest medical research project of the 21st century","volume":"49","author":"Kurup","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_67","first-page":"e936523","article-title":"Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants","volume":"28","author":"Parums","year":"2022","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e0142322","DOI":"10.1128\/mbio.01423-22","article-title":"A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern","volume":"13","author":"Schultz","year":"2022","journal-title":"mBio"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"de la Torre, J.C.G., C\u00e1ceres-DelAguila, J.A., Muro-Rojo, C., De La Cruz-Escurra, N., Copaja-Corzo, C., Hueda-Zavaleta, M., Arenas Siles, D., and Benites-Zapata, V.A. (2022). Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study. Trop. Med. Infect. Dis., 7.","DOI":"10.3390\/tropicalmed7050066"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s42269-022-00719-x","article-title":"A review on the induction of host immunity by the current COVID-19 vaccines and a brief non-pharmaceutical intervention to mitigate the pandemic","volume":"46","author":"Noor","year":"2022","journal-title":"Bull. Natl. Res. Cent."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s40588-021-00162-y","article-title":"Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines","volume":"8","author":"Noor","year":"2021","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s42269-022-00945-3","article-title":"How do the severe acute respiratory coronavirus 2 (SARS-CoV-2) and its variants escape the host protective immunity and mediate pathogenesis?","volume":"46","author":"Noor","year":"2022","journal-title":"Bull. Natl. Res. Cent."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Muena, N.A., Garc\u00eda-Salum, T., Pardo-Roa, C., Serrano, E.F., Levican, J., Avenda\u00f1o, M.J., Almonacid, L.I., Valenzuela, G., Poblete, E., and Strohmeier, S. (2021). Long-lasting neutralizing antibody responses in SARS-CoV-2 seropositive individuals are robustly boosted by immunization with the CoronaVac and BNT162b2 vaccines. medRxiv.","DOI":"10.1101\/2021.05.17.21257197"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"791660","DOI":"10.3389\/fcimb.2021.791660","article-title":"Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"807454","DOI":"10.3389\/fimmu.2022.807454","article-title":"Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Chavda, V.P., Bezbaruah, R., Athalye, M., Parikh, P.K., Chhipa, A.S., Patel, S., and Apostolopoulos, V. (2022). Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses, 14.","DOI":"10.3390\/v14040759"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/11\/2541\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:20:08Z","timestamp":1760145608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/11\/2541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":79,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["v14112541"],"URL":"https:\/\/doi.org\/10.3390\/v14112541","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]}}}